Biotech | August 17, 2021
Indian pharma’s vaccine opportunity at US $ 10-11 billion
Domestic market and developing countries will need doses of Indian vaccines
Domestic market and developing countries will need doses of Indian vaccines
Demand normalisation post the second wave contributed to the steady growth
The collaboration will support Canada with direct access to rapid pandemic response capabilities
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Filing for WHO Emergency Use Authorisation this month
CDSCO to fast-track trials and approval for COVID19 vaccine
AstraZeneca, Sinopharm and Moderna were part of the study
Five seats reserved for Wards of COVID warriors in central MBBS admission
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
